Document
IPR2023-00724, No. 2549 Exhibit - EX2549 Email Notice of Electronic Filing Corresponding to In re Ozempic Semaglutide Patent Litigation, No 122 cv 03038 CFC Dkt 334 (P.T.A.B. Jul. 31, 2024...
Cite Document
IPR2023-00724, No. 2549 Exhibit - EX2549 Email Notice of Electronic Filing Corresponding to In re Ozempic Semaglutide Patent Litigation, No 122 cv 03038 CFC Dkt 334 (P.T.A.B. Jul. 31, 2024)
+ More Snippets
Document
IPR2023-00724, No. 2005 Exhibit - EX2005 Knight, A, “Systematic Reviews of Animal Experiments Demonstrate Poor Contributions Toward Human Healthcare,” Reviews on Recent Clinical Trial...
Cite Document
IPR2023-00724, No. 2005 Exhibit - EX2005 Knight, A, “Systematic Reviews of Animal Experiments Demonstrate Poor Contributions Toward Human Healthcare,” Reviews on Recent Clinical Trials, Vol3, Issue
+ More Snippets
Document
IPR2023-00724, No. 2535 Exhibit - EX2535 Declaration of Jenny C Wu (P.T.A.B. Apr. 10, 2024)
Cite Document
IPR2023-00724, No. 2535 Exhibit - EX2535 Declaration of Jenny C Wu (P.T.A.B. Apr. 10, 2024)
+ More Snippets
Document
IPR2023-00724, No. 2079 Exhibit - EX2079 United States Patent and Trademark Office, Consolidated Trial Practice Guide, Appendix B Default Protective Order November 2019 (P.T.A.B. Jan. ...
Cite Document
IPR2023-00724, No. 2079 Exhibit - EX2079 United States Patent and Trademark Office, Consolidated Trial Practice Guide, Appendix B Default Protective Order November 2019 (P.T.A.B. Jan. 17, 2024)
+ More Snippets
Document
IPR2023-00724, No. 2016 Exhibit - EX2016 Mehdi, S, et al, “Glucagon like peptide 1 a multi faceted anti inflammatory agent,” Frontiers in Immunology, Vol 14 2023 (P.T.A.B. Jan. 17, 2024)
Cite Document
IPR2023-00724, No. 2016 Exhibit - EX2016 Mehdi, S, et al, “Glucagon like peptide 1 a multi faceted anti inflammatory agent,” Frontiers in Immunology, Vol 14 2023 (P.T.A.B. Jan. 17, 2024)
+ More Snippets
Document
IPR2023-00724, No. 2514 Exhibit - EX2514 Novo Nordisk, Financial report for the period 1 January 2023 to 31 March 2023 May 4, 2023 (P.T.A.B. Jan. 17, 2024)
Cite Document
IPR2023-00724, No. 2514 Exhibit - EX2514 Novo Nordisk, Financial report for the period 1 January 2023 to 31 March 2023 May 4, 2023 (P.T.A.B. Jan. 17, 2024)
+ More Snippets
Document
IPR2023-00724, No. 2076 Exhibit - EX2076 Ozempic® Prescribing Information March 2022 (P.T.A.B. Jan. 17, 2024)
Cite Document
IPR2023-00724, No. 2076 Exhibit - EX2076 Ozempic® Prescribing Information March 2022 (P.T.A.B. Jan. 17, 2024)
+ More Snippets
Document
IPR2023-00724, No. 2495 Exhibit - EX2495 Novo Nordisk, Financial report for the period 1 January 2018 to 30 June 2018 Aug 8, 2018 (P.T.A.B. Jan. 17, 2024)
Cite Document
IPR2023-00724, No. 2495 Exhibit - EX2495 Novo Nordisk, Financial report for the period 1 January 2018 to 30 June 2018 Aug 8, 2018 (P.T.A.B. Jan. 17, 2024)
+ More Snippets
Document
IPR2023-00724, No. 2104 Exhibit - EX2104 Maskery, MP, et al, Glucagon like peptide 1 receptor agonists as neuroprotective agents for ischemic stroke a systematic scoping review, J Cereb Bl...
Cite Document
IPR2023-00724, No. 2104 Exhibit - EX2104 Maskery, MP, et al, Glucagon like peptide 1 receptor agonists as neuroprotective agents for ischemic stroke a systematic scoping review, J Cereb Blood Flow M
+ More Snippets
Document
IPR2023-00724, No. 2603 Exhibit - EX2603 S Coca et al, Role of Intensive Glucose Control in Development of Re nal End Points in Type 2 Diabetes Mellitus, Arch Intern Med Vol 172 2012 Marke...
Cite Document
IPR2023-00724, No. 2603 Exhibit - EX2603 S Coca et al, Role of Intensive Glucose Control in Development of Re nal End Points in Type 2 Diabetes Mellitus, Arch Intern Med Vol 172 2012 Marked As Exhib
+ More Snippets
Document
IPR2023-00724, No. 2366-2 Exhibit - EX2366 Cleveland Clinic, “Biguanides,” httpsmyclevelandclinicorghealthtreatments25004 biguanides, last reviewed May 22, 2023 (P.T.A.B. Jan. 17, 2024)
Cite Document
IPR2023-00724, No. 2366-2 Exhibit - EX2366 Cleveland Clinic, “Biguanides,” httpsmyclevelandclinicorghealthtreatments25004 biguanides, last reviewed May 22, 2023 (P.T.A.B. Jan. 17, 2024)
+ More Snippets
Document
IPR2023-00724, No. 2099 Exhibit - EX2099 Kleindorfer, DO, et al, Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack, Stroke, 52e364–e467 2021 (P.T....
Cite Document
IPR2023-00724, No. 2099 Exhibit - EX2099 Kleindorfer, DO, et al, Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack, Stroke, 52e364–e467 2021 (P.T.A.B. Jan.
+ More Snippets
Document
IPR2023-00724, No. 2444 Exhibit - EX2444 US Food Drug Administration, DrugsFDA, Invokamet® XR (P.T.A.B. Jan. 17, 2024)
Cite Document
IPR2023-00724, No. 2444 Exhibit - EX2444 US Food Drug Administration, DrugsFDA, Invokamet® XR (P.T.A.B. Jan. 17, 2024)
+ More Snippets
Document
IPR2023-00724, No. 2372 Exhibit - EX2372 Eggleton, JS and Jialal, I, Thiazolidinediones, StatPearls Internet, available at httpswwwncbinlmnihgovbooksNBK551656, last updated Feb 20, 2023...
Cite Document
IPR2023-00724, No. 2372 Exhibit - EX2372 Eggleton, JS and Jialal, I, Thiazolidinediones, StatPearls Internet, available at httpswwwncbinlmnihgovbooksNBK551656, last updated Feb 20, 2023 (P.T.A.B. Ja
+ More Snippets
Document
IPR2023-00724, No. 2006 Exhibit - EX2006 Arrowsmith, J, “Phase II failures 2008–2010,” Nature Reviews, Drug Discovery, Vol 10 May 2011 (P.T.A.B. Jul. 6, 2023)
Cite Document
IPR2023-00724, No. 2006 Exhibit - EX2006 Arrowsmith, J, “Phase II failures 2008–2010,” Nature Reviews, Drug Discovery, Vol 10 May 2011 (P.T.A.B. Jul. 6, 2023)
+ More Snippets